New research into importance of skin surveillance to save lives from melanoma
4 November 2021
New research has provided evidence that routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma – the most deadly form of skin cancer.
Australia has the highest melanoma rates in the world, with one person dying every 6 hours from the disease. Melanoma is also the most common cancer in 20 to 39-year-olds.
The first sign of melanoma is often a new or changing spot or mole on the skin, and the ABCDE guidelines are a helpful tool to identify a melanoma. However, melanoma can vary greatly in its appearance and many subtle clues can only be detected by a trained healthcare professional using a magnifying tool, known as a dermatoscope, to check the skin.
The research, published today in the prestigious journal JAMA Dermatology, found that in a group of 2,452 patients diagnosed with melanoma, slower-growing melanomas were more likely to be detected at a routine skin check and be thinner, whereas faster-growing melanomas were more likely to be patient-detected and thicker. It was estimated that patients whose melanoma was detected by their doctor during a routine skin check were 32% less likely to die from melanoma compared to patients who identified their own melanoma.
The study also found that melanomas easily detected using the ABCDE rule were more likely to be detected by the patients (70%), whereas atypical ones were more often detected by a doctor during a routine skin check.
“This evidence highlights the importance of not only knowing your own skin and seeking advice from your doctor if you notice any changes but also the critical role of trained healthcare professionals for detecting melanomas early, before they have had a chance to spread,” said study author Prof Richard Scolyer AO, pathologist and Co-Medical Director of Melanoma Institute Australia.
Current Australian guidelines recommend that individuals at very high risk of melanoma receive full skin examinations every 6 months. However, melanoma screening programs for the general population are not currently undertaken in Australia because of inadequate evidence that melanoma screening ultimately saves lives, uncertainty about overdiagnosis and unnecessary biopsy, and limited evidence that it is cost effective.
In the last decade there has been renewed interest in melanoma screening, driven by the changing landscape of melanoma care.
“We found that melanoma detection during a routine skin check was associated with lower risk of dying from any cause, but it was not statistically significant for melanoma-specific mortality,” said cancer epidemiologist and lead author Prof Anne Cust, from Melanoma Institute Australia, The Daffodil Centre and The University of Sydney. “Based on our early findings, the cost-effectiveness of a population melanoma screening program should be re-assessed, and a large randomised controlled trial is needed to provide definitive evidence.”
Melanoma Institute Australia has recently launched its ‘Game On Mole’ awareness campaign which uses slogan t-shirts to start conversations about melanoma early detection, and urges Australians to take photos of their skin and monitor for any changes.
To join the campaign and buy the ‘Game On Mole’ t-shirt, go to www.gameonmole.com.au.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.